
    
      This is an observational, multi-center, prospective, cohort study, where no visits or
      intervention(s) additional to the daily practice will be performed. In the study sites,
      patients undergoing routine clinical care for RRMS and initiated treatment with Generic DMF
      (Sclera® or Marovarex ®, Hikma) in accordance with the approved SPC will be followed up and
      assessed for a total of 12 months.
    
  